WO2007057508A3 - Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol - Google Patents
Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol Download PDFInfo
- Publication number
- WO2007057508A3 WO2007057508A3 PCT/FI2006/000378 FI2006000378W WO2007057508A3 WO 2007057508 A3 WO2007057508 A3 WO 2007057508A3 FI 2006000378 W FI2006000378 W FI 2006000378W WO 2007057508 A3 WO2007057508 A3 WO 2007057508A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor agonist
- opioid receptor
- treatment
- pain
- adrenoceptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Abstract
This invention relates to use of an α2-adrenoceptor antagonist for the preparation of a medicament for treating a mammal, including human, to augment the action of a µ-opioid receptor agonist in the treatment of pain, susceptible to treatment with a µ-opioid receptor agonist, and said µ-opioid receptor agonist is a weakly efficacious µ-opioid receptor agonist or a moderately efficacious µ-opioid receptor agonist. This invention also relates to a corresponding method for the treatment or prevention of pain in a mammal, including human. This invention further relates to pharmaceutical preparations. The preparations comprise a weakly efficacious µ-opioid receptor agonist or a moderately efficacious µ-opioid receptor agonist, and a α2-adrenoceptor antagonist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73774005P | 2005-11-18 | 2005-11-18 | |
US60/737,740 | 2005-11-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007057508A2 WO2007057508A2 (en) | 2007-05-24 |
WO2007057508A3 true WO2007057508A3 (en) | 2008-03-27 |
Family
ID=37876013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2006/000378 WO2007057508A2 (en) | 2005-11-18 | 2006-11-17 | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007057508A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012136969A2 (en) * | 2011-04-05 | 2012-10-11 | Anant Sharma | Ophthalmic treatments |
EP2821072A1 (en) * | 2013-07-01 | 2015-01-07 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord disorders |
CN110251496A (en) | 2013-09-06 | 2019-09-20 | 蒙大拿大学 | The method for reducing Neuronal cell death with halogenated alkyl amine |
JP6876003B2 (en) | 2015-02-27 | 2021-05-26 | デクラ リミテッド | Stimulation of appetite, management of weight loss, and treatment of anorexia nervosa in dogs and cats |
DE18205817T1 (en) | 2018-11-13 | 2020-12-24 | Gtx Medical B.V. | SENSOR IN CLOTHING OF LIMBS OR FOOTWEAR |
EP3653256B1 (en) | 2018-11-13 | 2022-03-30 | ONWARD Medical N.V. | Control system for movement reconstruction and/or restoration for a patient |
CN116115739B (en) * | 2022-12-29 | 2024-01-09 | 天津市肿瘤医院(天津医科大学肿瘤医院) | Motilin and application of receptor agonist thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007025383A1 (en) * | 2005-08-30 | 2007-03-08 | Queen's University At Kingston | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist |
-
2006
- 2006-11-17 WO PCT/FI2006/000378 patent/WO2007057508A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007025383A1 (en) * | 2005-08-30 | 2007-03-08 | Queen's University At Kingston | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist |
Non-Patent Citations (6)
Title |
---|
AGEEL A M ET AL: "YOHIMBINE PROLONGS THE DURATION OF ANTINOCICEPTIVE ACTIVITY OF MORPHINE IN MICE", INDIAN JOURNAL OF PHARMACOLOGY, XX, XX, vol. 16, 1984, pages 112 - 114, XP008078074, ISSN: 0253-7613 * |
AMBROSIO E ET AL: "Effect of yohimbine on the development of morphine dependence in the rat: Lack of involvement of cortical beta-androceptor modifications", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 56, no. 3, 1997, pages 487 - 491, XP003009171, ISSN: 0091-3057 * |
EL-KADI A O S ET AL: "The influence of chronic treatment with clonidine, yohimbine and idazoxan on morphine withdrawal", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 132, 1997, pages 67 - 73, XP003009173, ISSN: 0033-3158 * |
GEAR R W ET AL: "Enhancement of morphine analgesia by the alpha2-adrenergic antagonist yohimbine", NEUROSCIENCE, NEW YORK, NY, US, vol. 66, no. 1, 1995, pages 5 - 8, XP003009169, ISSN: 0306-4522 * |
HOMAYOUN H ET AL: "The role of alpha2-adrenoreceptors in the modulatory effects of morphine on seizure susceptibility in mice", EPILEPSIA, LIPPINCOTT, WILLIAMS AND WILKINS, PHILADELPHIA, PA, US, vol. 43, no. 8, 2002, pages 797 - 804, XP003009170, ISSN: 1528-1167 * |
OZDOGAN ET AL: "The analgesic efficacy of partial opioid agonists is increased in mice with targeted inactivation of the alpha2A-adrenoceptor gene", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 529, no. 1-3, 4 January 2006 (2006-01-04), pages 105 - 113, XP005229947, ISSN: 0014-2999 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007057508A2 (en) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007005716A3 (en) | Methods of treatment and compositions for use thereof | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
WO2005102338A8 (en) | Method of treating neuropathic pain using a crth2 receptor antagonist | |
WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
WO2007057508A3 (en) | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol | |
IL197420A (en) | Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one, methods for its preparation, a pharmaceutical composition containing it and uses of such form in the preparation of medicaments for treatment of the human body | |
WO2007002597A3 (en) | Modified-release formulations of a bupropion salt | |
PT2210588E (en) | Foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin | |
IL221795B (en) | Use of a pharmaceutical composition of methylnaltrexone, or a salt thereof, in the preparation of a medicament for treating the side effects of opioid treatment | |
WO2007087068A3 (en) | Inhibitors of tyrosine kinases and uses thereof | |
WO2003070191A3 (en) | Tamper-resistant transdermal opioid delivery devices | |
WO2008128126A8 (en) | Compositions and methods for prophylaxis and treatment of addictions | |
WO2006089114A3 (en) | Methods and compositions for treating an anthrax toxin mediated condition | |
WO2008133928A3 (en) | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders | |
WO2014165607A3 (en) | Aromatic-cationic peptide formulations, compositions and methods of use | |
WO2006086693A3 (en) | Medical devices | |
IL207559A0 (en) | Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease | |
BRPI0921097A2 (en) | pyrazol-3 carboxamide derivative compound with 5-ht2b receptor antagonist activity, preventive or therapeutic agent, pharmaceutical composition and use of the compound or pharmaceutically acceptable salt thereof and method or prevention or treatment. | |
SG149872A1 (en) | Antagonists of the bradykinin b1 receptor | |
WO2007006732A8 (en) | Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) | |
WO2008016640A3 (en) | Use of poloxamer for the prevention and/or treatment of heart failure | |
WO2009047513A3 (en) | Antagonists of kisspeptin and uses thereof | |
WO2006116311A3 (en) | Opioid receptor agonist compounds and their use in treatment of pain | |
WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06820059 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06820059 Country of ref document: EP Kind code of ref document: A2 |